New data from the PROCLIPI study has shown a meaningful overall survival benefit for patients with advanced cutaneous T-cell ...

ENA Respiratory has raised US$22.4m (AU$34m) in Series B financing to support the phase 2 clinical development of its nasal spray therapy, INNA-051. The Melbourne-based pharmaceutical company welcomed ...

Nxera Pharma and its partner Cancer Research UK have presented encouraging results from the completed phase 1 portion of ...

The Global Fund has welcomed a £6 million joint investment from GSK and ViiV Healthcare to strengthen community-led responses ...

Janssen-Cilag International NV, part of Johnson & Johnson, has announced encouraging results from the phase 1b/2 OrigAMI-4 ...

Artificial intelligence tools that could revolutionise patient care are being trialled in phase 2 of the Medicines and ...

AstraZeneca’s Saphnelo (anifrolumab) has received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) for approval in the European Union as a self-administered, ...

Men with BRCA1 and BRCA2 gene mutations should be offered annual PSA testing from the age of 40 to detect prostate cancer at ...

Enterome has received fast track designation from the US Food and Drug Administration for its lead OncoMimics immunotherapy EO2463, targeting follicular lymphoma in the low tumour burden ...